Head to head
The Chemours vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: CC · LIN
CC
The Chemours
13.98-0.71%
1-year price shape — -5% over the period
Quant Rating D · 28/100
vs
LIN
Linde
483.98-1.22%
1-year price shape — +4% over the period
Quant Rating D · 45/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde has the highest Quant Rating (45); Linde has done best over the past year (+4%); Linde earns the most per share.
| CC | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Specialty Chemicals |
| Last price | 13.98 | 483.98 |
| Change today | -0.71% | -1.22% |
| 1-year return | -5.3% | +4.3% |
| Market cap | $2.10B | $223.11B |
| 52-week range | 10.29 – 28.41 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | -6.92 | 31.22 |
| P/E percentile, own 5-yr range | 32nd | 8th |
| P/B | -42.88 | 5.71 |
| Dividend yield | 2.50% | 1.28% |
| Profitability & growth | ||
| EPS (TTM) | -2.57 | 14.61 |
| Net profit (TTM) | $-386.78M | $6.73B |
| Revenue (TTM) | $5.80B | $35.45B |
| Revenue growth (YoY) | -1.5% | +9.3% |
| Gross margin | 15.3% | 48.3% |
| Operating margin | -1.9% | 27.1% |
| Net margin | -5.2% | 20.4% |
| Free cash flow (TTM) | $218.00M | $4.98B |
| Ownership & sentiment | ||
| Institutional ownership | 90.9% | 88.0% |
| Insider activity (12mo) | 33 buy / 16 sell | 33 buy / 13 sell |
| Short interest (% of float) | 10.5% | 1.3% |
| Analyst consensus | 62% buy / 38% hold (8) | 87% buy / 13% hold (15) |
| Analyst price target | $19 (+34%) | $557 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (28) | D (45) |
| Company | ||
| Employees | 5,700 | 65,177 |
| Founded | 2014 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.